RxDoctor Payments Data

Shashank Bhatt, MD

Internal Medicine · Montrose, PANPI 1023189818

Payments from drug & device makers

$11,524in general payments, 2019–2025

Across 699 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • Novo Nordisk$772
  • Lilly USA, LLC$742
  • Astellas Pharma US Inc$695
  • Pfizer$688
  • plus $6K from 53 others

What the payments were for

  • Food & beverage$11,524100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)87$1,149
Amgen66$1,008
Novo Nordisk58$772
Lilly USA, LLC45$742
Astellas Pharma US Inc36$695
Pfizer53$688
GSK34$598
Boehringer Ingelheim32$574
AstraZeneca17$502
Exact Sciences18$365
Shield Therapeutics Inc20$340
Teva Pharmaceuticals USA, Inc.15$240
Abbott15$224
Bayer12$220
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$212
Merck11$187
Alnylam Pharmaceuticals Inc.9$186
Sumitomo Pharma America, Inc.10$178
Corcept Therapeutics7$173
Currax Pharmaceuticals LLC10$167
Novartis9$162
Sanofi-aventis U.S. LLC9$159
Biohaven Pharmaceutical Holding Company Ltd.10$132
Amarin Pharma, Inc.9$131
Orexo US, Inc.8$128
Idorsia Pharmaceuticals US Inc5$112
Nestle Healthcare Nutrition Inc.6$111
Insulet Corporation4$94
Otsuka America Pharmaceutical, Inc.5$85
Takeda Pharmaceuticals U.S.A., Inc.5$84
Axsome Therapeutics, Inc.4$82
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$76
Alk-abello, Inc2$71
Corium, LLC4$69
Biohaven Pharmaceuticals, Inc.4$63
Paratek Pharmaceuticals, Inc.4$63
Grifols USA, LLC3$56
Inspire Medical Systems, Inc.3$56
Dexcom, Inc.2$55
Phathom Pharmaceuticals, Inc.3$44
Xeris Pharmaceuticals, Inc.2$42
Aimmune Therapeutics, Inc.2$41
Vapotherm Inc1$37
Supernus Pharmaceuticals, Inc.2$32
Verona Pharma, Inc.2$31
Arbor Pharmaceuticals, Inc.2$31
Mylan Specialty L.p.2$29
Ardelyx, Inc.1$29
Intuitive Surgical1$27
Daiichi Sankyo Inc.1$27
Genentech USA, Inc.2$26
Lundbeck LLC1$21
Boston Scientific1$15
Medtronic1$15
Sanofi1$15
IBSA Pharma Inc.1$14
Tolmar, Inc.1$13
Collegium Pharmaceutical, Inc.1$13
Johnson & Johnson1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,524 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$137,906
Medicare patients
418
Services billed
2,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide188$287,553
JardianceEmpagliflozin110$147,956
EliquisApixaban126$108,305
TradjentaLinagliptin49$65,241
MyrbetriqMirabegron65$51,513
TrulicityDulaglutide23$39,858
MounjaroTirzepatide26$37,180
GlyxambiEmpagliflozin/Linagliptin30$26,502
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog42$24,914
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,868
Spiriva RespimatTiotropium Bromide25$20,201
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$19,991
XareltoRivaroxaban21$16,894
Breo ElliptaFluticasone/Vilanterol30$16,759
TrintellixVortioxetine Hydrobromide13$16,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$772$302,152199 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Spiriva Respimat, Combivent Respimat$574$274,592225 claims
PfizerEliquis, Lyrica$688$117,918137 claims
Lilly USA, LLCTrulicity, Mounjaro$742$77,03849 claims
Astellas Pharma US IncMyrbetriq$695$51,51365 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$598$49,41284 claims
AstraZenecaBreztri Aerosphere, Symbicort$502$18,77741 claims
Johnson & JohnsonXarelto$12$16,89421 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$84$16,46013 claims
MerckJanumet$187$13,25014 claims
AbbVieSynthroid$1,149$2,61454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Montrose

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →